Đang chuẩn bị liên kết để tải về tài liệu:
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative invitro model

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Anticancer compound 3-bromopyruvate (3-BrPA) suppresses cancer cell growth via targeting glycolytic and mitochondrial metabolism. The malignant peripheral nerve sheath tumor (MPNST), a very aggressive, therapy resistant, and Neurofibromatosis type 1 associated neoplasia, shows a high metabolic activity and affected patients may therefore benefit from 3-BrPA treatment. |

TÀI LIỆU LIÊN QUAN

The novel IGF-IR/Akt–dependent anticancer activities of glucosamine

Synthesis of novel SN38-aspirin prodrugs for the treatment of hepatocellular carcinoma

Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer

Tolerance to oral anticancer agent treatment in older adults with cancer: A secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes

Báo cáo hóa học: " Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent"

Báo cáo hóa học: " 2D and 3D-QSAR study on 4-anilinoquinozaline derivatives as potent apoptosis inducer and efficacious anticancer agent"

A novel synthesis, X-ray analysis and computational studies of (Z)-ethyl 2-((Z)-5-((dimethylamino)methylene)- 4-oxo-3-phenylthiazolidin-2-ylidene)acetate as a potential anticancer agent

Synthesis, spectroscopic, dielectric, molecular docking and DFT studies of (3E)-3-(4-methylbenzylidene)-3,4-dihydro2H-chromen-2-one: An anticancer agent

Finding an efficient tetramethylated hydroxydiethylene of resveratrol analogue for potential anticancer agent

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment